Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Quinine compared to 4β-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin.

Björkhem-Bergman L, Bäckström T, Nylén H, Rönquist-Nii Y, Bredberg E, Andersson TB, Bertilsson L, Diczfalusy U.

Drug Metab Pharmacokinet. 2014;29(4):352-5. Epub 2014 Feb 11.

2.

Comparison of endogenous 4β-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin.

Björkhem-Bergman L, Bäckström T, Nylén H, Rönquist-Nii Y, Bredberg E, Andersson TB, Bertilsson L, Diczfalusy U.

Drug Metab Dispos. 2013 Aug;41(8):1488-93. doi: 10.1124/dmd.113.052316. Epub 2013 May 14.

PMID:
23674608
3.

Sleep Health Issues for Children with FASD: Clinical Considerations.

Jan JE, Asante KO, Conry JL, Fast DK, Bax MC, Ipsiroglu OS, Bredberg E, Loock CA, Wasdell MB.

Int J Pediatr. 2010;2010. pii: 639048. doi: 10.1155/2010/639048. Epub 2010 Jul 14.

4.

4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin.

Diczfalusy U, Kanebratt KP, Bredberg E, Andersson TB, Böttiger Y, Bertilsson L.

Br J Clin Pharmacol. 2009 Jan;67(1):38-43. doi: 10.1111/j.1365-2125.2008.03309.x. Epub 2008 Nov 6.

5.

Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol.

Kanebratt KP, Diczfalusy U, Bäckström T, Sparve E, Bredberg E, Böttiger Y, Andersson TB, Bertilsson L.

Clin Pharmacol Ther. 2008 Nov;84(5):589-94. doi: 10.1038/clpt.2008.132. Epub 2008 Jul 23.

PMID:
18650803
6.

An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates.

Andersson TB, Bredberg E, Ericsson H, Sjöberg H.

Drug Metab Dispos. 2004 Jul;32(7):715-21.

PMID:
15205386
7.

Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions.

Bredberg E, Andersson TB, Frison L, Thuresson A, Johansson S, Eriksson-Lepkowska M, Larsson M, Eriksson UG.

Clin Pharmacokinet. 2003;42(8):765-77.

PMID:
12846597
8.

Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study.

Hallerbäck BI, Bommelaer G, Bredberg E, Campbell M, Hellblom M, Lauritsen K, Wienbeck M, Holmgren LL.

Aliment Pharmacol Ther. 2002 May;16(5):959-67.

9.

Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole.

Andersson T, Röhss K, Bredberg E, Hassan-Alin M.

Aliment Pharmacol Ther. 2001 Oct;15(10):1563-9.

10.

Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects.

Hassan-Alin M, Andersson T, Bredberg E, Röhss K.

Eur J Clin Pharmacol. 2000 Dec;56(9-10):665-70.

PMID:
11214773
11.

Lack of drug-drug interaction between three different non-steroidal anti-inflammatory drugs and omeprazole.

Andersson T, Bredberg E, Lagerström PO, Naesdal J, Wilson I.

Eur J Clin Pharmacol. 1998 Jul;54(5):399-404.

PMID:
9754983
12.

Metabolism and excretion of ropivacaine in humans.

Halldin MM, Bredberg E, Angelin B, Arvidsson T, Askemark Y, Elofsson S, Widman M.

Drug Metab Dispos. 1996 Sep;24(9):962-8.

PMID:
8886605
13.

Pharmacokinetics of levodopa and carbidopa in rats following different routes of administration.

Bredberg E, Lennernäs H, Paalzow L.

Pharm Res. 1994 Apr;11(4):549-55.

PMID:
8058614
14.

Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease.

Bredberg E, Nilsson D, Johansson K, Aquilonius SM, Johnels B, Nyström C, Paalzow L.

Eur J Clin Pharmacol. 1993;45(2):117-22.

PMID:
8223831
15.

Cerebral uptake and utilization of therapeutic [beta-11C]-L-DOPA in Parkinson's disease measured by positron emission tomography. Relations to motor response.

Tedroff J, Aquilonius SM, Hartvig P, Bredberg E, Bjurling P, Långström B.

Acta Neurol Scand. 1992 Feb;85(2):95-102.

PMID:
1574995
16.
18.

Pharmacokinetics and effects of levodopa in advanced Parkinson's disease.

Bredberg E, Tedroff J, Aquilonius SM, Paalzow L.

Eur J Clin Pharmacol. 1990;39(4):385-9. Erratum in: Eur J Clin Pharmacol 1990;39(6):576.

PMID:
2076722

Supplemental Content

Loading ...
Support Center